The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer

[1]  I. Ellis,et al.  A key genomic subtype associated with lymphovascular invasion in invasive breast cancer , 2019, British Journal of Cancer.

[2]  R. Piva,et al.  Wild-Type IDH Enzymes as Actionable Targets for Cancer Therapy , 2019, Cancers.

[3]  J. Mellor,et al.  IDH1: Linking Metabolism and Epigenetics , 2018, Front. Genet..

[4]  A. Bode,et al.  Wild-type IDH2 promotes the Warburg effect and tumor growth through HIF1α in lung cancer , 2018, Theranostics.

[5]  Kylie L. Gorringe,et al.  Thioredoxin-interacting protein is an independent risk stratifier for breast ductal carcinoma in situ , 2018, Modern Pathology.

[6]  I. Ellis,et al.  Saccharomyces cerevisiae-like 1 (SEC14L1) is a prognostic factor in breast cancer associated with lymphovascular invasion , 2018, Modern Pathology.

[7]  M. Watanabe,et al.  The prognostic value of regulatory T cells infiltration in HER2-enriched breast cancer microenvironment , 2018, International reviews of immunology.

[8]  I. Ellis,et al.  The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours , 2018, Breast Cancer Research.

[9]  I. Ellis,et al.  The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes , 2018, British Journal of Cancer.

[10]  S. Teoh,et al.  Metabolism in cancer metastasis: bioenergetics, biosynthesis, and beyond , 2018, Wiley interdisciplinary reviews. Systems biology and medicine.

[11]  Jyh‐cherng Yu,et al.  Prognostic role of lymphovascular invasion and lymph node status among breast cancer subtypes , 2018 .

[12]  I. Ellis,et al.  MYC regulation of glutamine–proline regulatory axis is key in luminal B breast cancer , 2017, British Journal of Cancer.

[13]  G. Ball,et al.  Prognostic stratification of oestrogen receptor‐positive HER2‐negative lymph node‐negative class of breast cancer , 2017, Histopathology.

[14]  G. Pond,et al.  Claudin-Low Breast Cancer; Clinical & Pathological Characteristics , 2017, PloS one.

[15]  Julie M. Batten,et al.  IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity. , 2016, Cancer research.

[16]  M. Gong,et al.  The relationship of lymphatic vessel density, lymphovascular invasion, and lymph node metastasis in breast cancer: a systematic review and meta-analysis , 2016, Oncotarget.

[17]  Shing M. Lee,et al.  Lymphovascular invasion is an independent predictor of survival in breast cancer after neoadjuvant chemotherapy , 2016, Breast Cancer Research and Treatment.

[18]  G. Ball,et al.  MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours , 2016, British Journal of Cancer.

[19]  Steven J. M. Jones,et al.  Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer , 2015, Cell.

[20]  Kylie L. Gorringe,et al.  Copy number analysis of ductal carcinoma in situ with and without recurrence , 2015, Modern Pathology.

[21]  A. Mukherjee,et al.  Molecular Mechanisms Underlying Lymphovascular Invasion in Invasive Breast Cancer , 2015, Pathobiology.

[22]  Genevieve Housman,et al.  EMT and tumor metastasis , 2015, Clinical and Translational Medicine.

[23]  John M S Bartlett,et al.  Updated UK Recommendations for HER2 assessment in breast cancer , 2014, Journal of Clinical Pathology.

[24]  Daniel Birnbaum,et al.  Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization , 2014, Molecular Cancer.

[25]  Sarah J. Kurley,et al.  MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. , 2014, The Journal of clinical investigation.

[26]  F. Zeman,et al.  Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry , 2013, Breast Cancer Research and Treatment.

[27]  Carlos Caldas,et al.  A new genome‐driven integrated classification of breast cancer and its implications , 2013, The EMBO journal.

[28]  Hiroko Masuda,et al.  Role of epidermal growth factor receptor in breast cancer , 2012, Breast Cancer Research and Treatment.

[29]  D. Sabatini,et al.  Cancer cell metabolism: one hallmark, many faces. , 2012, Cancer discovery.

[30]  F. Gao,et al.  Altered expression levels of IDH2 are involved in the development of colon cancer , 2012, Experimental and therapeutic medicine.

[31]  I. Ellis,et al.  The prognostic significance of lymphovascular invasion in invasive breast carcinoma , 2012, Cancer.

[32]  K. Smolková,et al.  The Role of Mitochondrial NADPH-Dependent Isocitrate Dehydrogenase in Cancer Cells , 2012, International journal of cell biology.

[33]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[34]  P. Ward,et al.  Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. , 2012, Cancer cell.

[35]  I. Ellis,et al.  Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer , 2011, Breast Cancer Research and Treatment.

[36]  Jia Liu,et al.  Twist2 contributes to breast cancer progression by promoting an epithelial–mesenchymal transition and cancer stem-like cell self-renewal , 2011, Oncogene.

[37]  I. Ellis,et al.  Objective assessment of lymphatic and blood vascular invasion in lymph node‐negative breast carcinoma: findings from a large case series with long‐term follow‐up , 2011, The Journal of pathology.

[38]  Shu Ichihara,et al.  Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists , 2011, Modern Pathology.

[39]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[40]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  A. Bednarek,et al.  Basal keratin expression in breast cancer by quantification of mRNA and by immunohistochemistry , 2010, Journal of experimental & clinical cancer research : CR.

[42]  W. Wheaton,et al.  Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity , 2010, Proceedings of the National Academy of Sciences.

[43]  R. Matkowski,et al.  The prognostic role of tumor-infiltrating CD4 and CD8 T lymphocytes in breast cancer. , 2009, Anticancer research.

[44]  N. Crawford,et al.  Mechanisms of metastasis , 2008, Breast Cancer Research.

[45]  Koji Kadota,et al.  A weighted average difference method for detecting differentially expressed genes from microarray data , 2008, Algorithms for Molecular Biology.

[46]  M. J. van de Vijver,et al.  Classification of ductal carcinoma in situ by gene expression profiling , 2006, Breast Cancer Research.

[47]  Å. Borg,et al.  Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors , 2005, Modern Pathology.

[48]  G. Ball,et al.  High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses , 2005, International journal of cancer.

[49]  M. Imamura,et al.  N-Cadherin Expression and Epithelial-Mesenchymal Transition in Pancreatic Carcinoma , 2004, Clinical Cancer Research.

[50]  Stuart A. Aaronson,et al.  Exogenous Expression of N-Cadherin in Breast Cancer Cells Induces Cell Migration, Invasion, and Metastasis , 2000, The Journal of cell biology.

[51]  M. Lippman,et al.  Breast Cancer Research and Treatment , 2004, Breast Cancer Research and Treatment.